Glioblastoma (GBM) is a highly lethal disease with few treatment options, and is the most common and aggressive malignant brain tumour in adults. One emerging strategy that differs from conventional GBM therapies is metabolic pathway targeting. At present there has yet to be any research outlining a metabolic phenotype of disease via observation of key biomarkers.
To pave the way for future studies, it is key to establish what metabolic dysregulation looks like in a cohort of GBM patients to direct interventions. The main aim of the study is to establish a metabolic phenotype of primary glioblastoma. This work builds on previous research investigating key metabolic markers in healthy, disease-free participants.
The study is led by Andrew Scarborough- BSc (Hons), PgCert and Isabella Cooper- FnDNutr., BSc (Hons), AFHEA, AMRSB, AfENDO.
Brain Gain – with extraordinary survivor Andrew Scarborough Show #415 – Date: 23 Jun 2023
